Health Economics›Rhabdomyosarcoma pediatric›Low-risk all lines of therapy

Low-risk all lines of therapy

Rhabdomyosarcoma pediatric · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG D9602 Subgroup A Clinical Group 1 protocol Variant not yet assigned - COG protocol	—	R 26 605	84d	—	—	—	—	—
COG D9602 Subgroup A Clinical Group 2 protocol Variant not yet assigned - COG protocol	—	R 26 605	84d	—	—	—	—	—
COG D9602 Subgroup A Clinical Group 3 protocol Variant not yet assigned - COG protocol	—	R 26 605	84d	—	—	—	—	—
COG D9602 Subgroup B Clinical Group 1 protocol N/A - secondary systemic drug	—	R 364	84d	—	—	—	—	—
COG D9602 Subgroup B Clinical Group 2 protocol N/A - secondary systemic drug	—	R 364	84d	—	—	—	—	—
COG D9602 Subgroup B Clinical Group 3 protocol N/A - secondary systemic drug	—	R 364	84d	—	—	—	—	—

6 of 6 regimens shown